Trials / Active Not Recruiting
Active Not RecruitingNCT04280081
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 77 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The reason for this study is to see if the study drug selpercatinib is safe and effective in participants in China with rearranged during transfection (RET) fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Selpercatinib | Administered orally |
Timeline
- Start date
- 2020-03-16
- Primary completion
- 2021-03-25
- Completion
- 2027-11-01
- First posted
- 2020-02-21
- Last updated
- 2025-04-20
- Results posted
- 2022-06-02
Locations
13 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04280081. Inclusion in this directory is not an endorsement.